BioCentury on BioBusiness,
Emerging Company Profile
SeaChange's computational method predicts drug compound-target interactions
Related tables, figures and sidebars
SeaChange: Computing targets
Monday, July 9, 2012
Pharmaceuticals Inc. is developing a computational method called
similarity ensemble approach to predict small molecule-target interactions that
could speed preclinical toxicology testing and help guide the design of novel
compounds. The company has shown the technique can detect off-target
interactions for existing drugs, and now is hoping to use it to identify
repurposing opportunities and to eventually fill its own pipeline with novel
Similarity ensemble approach
(SEA) predicts whether a compound will bind a target by comparing the
similarity of the compound's chemical groups to other known ligands of the
target. The statistical comparison is based on the premise that drugs of
similar structure will bind similar targets.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]